ReviewInternational journal of molecular sciences2021
Strategies to Tackle Antimicrobial Resistance: The Example of
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Bibliometric analysis of Pseudomonas aeruginosa vaccine development highlighting research status, evolution, and future opportunities.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Identification of multiple Acinetobacter baumannii protein antigens as targets for potential immunotherapies using a novel protein microarray screening approach.PLoS pathogens · 2026Article
- Next-generation anti-infective drugs in the post-antibiotic era: focusing on anti-virulence agents targeting the bacterial quorum sensing system.Frontiers in cellular and infection microbiology · 2026Review
- Antimicrobial potency and additive effect of herbal antimicrobial compounds against Pseudomonas aeruginosa, a causative agent of bacteremia.Bioprocess and biosystems engineering · 2026Article
- Translational horizons in bacterial membrane vesicles: Hotspots and frontiers from basic medicine to clinical application by bibliometric analysis.Human vaccines & immunotherapeutics · 2025Review
- Assessment of the anti-biofilm effect of UV-C irradiation (254 nm) against healthcare associated infections related microorganisms.Frontiers in microbiology · 2025Article
- Autovaccine immunoprophylaxis in patients with neurogenic bladder experiencing recurrent urinary tract infections.Frontiers in immunology · 2025Article
- Polyphenol Analysis and Antibacterial Potentials of Twig Extracts ofInternational journal of molecular sciences · 2024Article
- Review
- Molecular Signature of Monocytes Shaped by theInternational journal of molecular sciences · 2024Article
- Oral Immunization with AttenuatedBiomolecules · 2023Article
- Biotics (Pre-, Pro-, Post-) and Uremic Toxicity: Implications, Mechanisms, and Possible Therapies.Toxins · 2023Review
- RND pump inhibition: in-silico and in-vitro study by Eugenol on clinical strain ofIn silico pharmacology · 2023Article
- Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial Infections.Vaccines · 2022Review
- A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa.Scientific reports · 2022Article
- Layered and integrated medical countermeasures againstFrontiers in microbiology · 2022Article
- What Is New in the Anti-Frontiers in cellular and infection microbiology · 2022Review
- DissectingFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional antimicrobial treatments consist of drugs which target different essential functions in pathogens. Nevertheless, bacteria continue to evolve new mechanisms to evade this drug-mediated killing with surprising speed on the deployment of each new drug and antibiotic worldwide, a phenomenon called antimicrobial resistance (AMR). Nowadays, AMR represents a critical health threat, for which new medical interventions are urgently needed. By 2050, it is estimated that the leading cause of death will be through untreatable AMR pathogens. Although antibiotics remain a first-line treatment, non-antibiotic therapies such as prophylactic vaccines and therapeutic monoclonal antibodies (mAbs) are increasingly interesting alternatives to limit the spread of such antibiotic resistant microorganisms. For the discovery of new vaccines and mAbs, the search for effective antigens that are able to raise protective immune responses is a challenging undertaking. In this context, outer membrane vesicles (OMV) represent a promising approach, as they recapitulate the complete antigen repertoire that occurs on the surface of Gram-negative bacteria. In this review, we present
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.